Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.64 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.64 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.64 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.64 |
| ▸ | CHRNA2 | Q15822 | 3/20 | 0.64 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.64 |
| ▸ | CHRNG | P07510 | 2/20 | 0.64 |
| ▸ | CHRND | Q07001 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.58 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.58 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.58 |
| ▸ | HTR3B | O95264 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31019621 | 1.00 | CHRNB4 (0.64) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL159159 | 1.00 | CHRNB4 (0.64) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL30866535 | 1.00 | CHRNB4 (0.64) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| Acetic Acid SCHEMBL27199916 | 0.91 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL20164036 | 0.91 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| Acetic Acid SCHEMBL31344159 | 0.91 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| Cadaverine Tartrate SCHEMBL30866584 | 0.87 | BLM (0.67) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| Lactic Acid SCHEMBL31344162 | 0.87 | BLM (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| L-Lactic Acid SCHEMBL27199878 | 0.87 | BLM (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| Lactic Acid SCHEMBL27199874 | 0.87 | BLM (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964958-B1 | Vaporizable alkaloid compositions and methods of use thereof | Ready Mix Naturals, LLC (US) | 2024-04-23 | — | — | US | claimed |
| JP-62081381-A | — | — | None | — | — | JP | disclosed |
| US-11964958-B1 | Vaporizable alkaloid compositions and methods of use thereof | Ready Mix Naturals, LLC (US) | 2024-04-23 | — | — | US | disclosed |
| US-20200236936-A1 | (S)-5-ETHYNYL-ANABASINE, DERIVATIVES THEREOF, AND RELATED COMPOSITIONS AND METHODS OF MAKING AND USING | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2020-07-30 | — | — | US | disclosed |
| US-10667515-B2 | (S)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190200611-A1 | (S)-5-ETHYNYL-ANABASINE, DERIVATIVES THEREOF, AND RELATED COMPOSITIONS AND METHODS OF MAKING AND USING | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20180139961-A1 | (S)-5-ETHYNYL-ANABASINE, DERIVATIVES THEREOF, AND RELATED COMPOSITIONS AND METHODS OF MAKING AND USING | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2018-05-24 | — | — | US | disclosed |
| EP-2611788-A2 | NICOTINE COMPOUNDS AND ANALOGS THEREOF, SYNTHETIC METHODS OF MAKING COMPOUNDS, AND METHODS OF USE | University of Florida Research Foundation, Incorporated (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012031220-A2 | NICOTINE COMPOUNDS AND ANALOGS THEREOF, SYNTHETIC METHODS OF MAKING COMPOUNDS, AND METHODS OF USE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| EP-1857121-A2 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | Xenova Research Limited (GB) | 2007-11-21 | — | — | EP | disclosed |
| CN-101014587-A | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORP (US) | 2007-08-08 | — | — | CN | disclosed |
| EP-1024834-A2 | HAPTEN-CARRIER CONJUGATES FOR USE IN DRUG-ABUSE THERAPY AND METHODS FOR PREPARATION OF SAME | IMMULOGIC PHARMACEUTICAL CORPORATION (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1998014216-A9 | HAPTEN-CARRIER CONJUGATES FOR USE IN DRUG-ABUSE THERAPY AND METHODS FOR PREPARATION OF SAME | — | 1998-08-13 | — | — | WO | disclosed |
| WO-1998014216-A2 | HAPTEN-CARRIER CONJUGATES FOR USE IN DRUG-ABUSE THERAPY AND METHODS FOR PREPARATION OF SAME | IMMULOGIC PHARMACEUTICAL CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
| EP-0559495-A1 | Treatment of neurodegenerative diseases | R.J. REYNOLDS TOBACCO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0559495-A1 | Treatment of neurodegenerative diseases | R.J. REYNOLDS TOBACCO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| US-5242935-A | Alzheimer*s disease, compounds with a pyridine and a pyrrole ring | R. J. REYNOLDS TOBACCO COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| US-5242935-A | Alzheimer*s disease, compounds with a pyridine and a pyrrole ring | R. J. REYNOLDS TOBACCO COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| JP-S6281381-A | NICOTINE DERIVATIVE AND PRODUCTION THEREOF | JAPAN TOBACCO INC | 1987-04-14 | — | — | JP | disclosed |
| US-4321387-A | Process for the preparation of optically active nicotine analogs | PHILIP MORRIS, INCORPORATED (US) | 1982-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964958-B1 | Vaporizable alkaloid compositions and methods of use thereof | SRM, SCLY, SMOX | CHRNB4 55/4885CHRNA3 116/4885CHRNB2 98/4885 |
| US-10667515-B2 | (S)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using | AAAS, NANS, CIAPIN1 | CHRNB4 2085/4885CHRNA3 2431/4885CHRNB2 2259/4885 |
| US-20190200611-A1 | (S)-5-ETHYNYL-ANABASINE, DERIVATIVES THEREOF, AND RELATED COMPOSITIONS AND METHODS OF MAKING AND USING | AAAS, NANS, CIAPIN1 | CHRNB4 2085/4885CHRNA3 2431/4885CHRNB2 2259/4885 |
| US-20200236936-A1 | (S)-5-ETHYNYL-ANABASINE, DERIVATIVES THEREOF, AND RELATED COMPOSITIONS AND METHODS OF MAKING AND USING | AAAS, NANS, CIAPIN1 | CHRNB4 2085/4885CHRNA3 2431/4885CHRNB2 2259/4885 |
| US-20180139961-A1 | (S)-5-ETHYNYL-ANABASINE, DERIVATIVES THEREOF, AND RELATED COMPOSITIONS AND METHODS OF MAKING AND USING | AAAS, NANS, CIAPIN1 | CHRNB4 2085/4885CHRNA3 2431/4885CHRNB2 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.